Allergan Plc: Continue to Strengthen Its Presence and Innovation in GI market

Reportedly, on Oct 3, 2016, Allegran Plc; headquartered in New Jersey (US) announced that it has entered into an exclusive worldwide licensing agreement with MedImmune (AstraZeneca’s R&D arm) to develop and commercialize MEDI2070 which finally get completed on Nov 17, 2016.

As per the terms of the agreement, Allergan will pay an upfront payment to AstraZeneca of $250 million for the license. In addition, Allergan may make potential payments to AstraZeneca of up to $1.27 billion, dependent on the achievement of agreed upon success and sales milestones. MedImmune has been leading the clinical development for MEDI2070 under a collaboration agreement with Amgen Inc. Thus as per the agreement, AstraZeneca will subsequently pay Amgen 1/3rd of all payments and royalties received from Allergan.

MEDI2070 is an anti-IL-23 monoclonal antibody in development for the treatment of patients with moderate to severe Crohn’s disease and Ulcerative Colitis, which is outside AstrsZenca’s above mentioned three therapy areas. Ulcerative colitis and Crohn’s disease are both long-term conditions with inflammation of the gut. Ulcerative colitis only affects the colon (large intestine), whereas Crohn’s disease affects all of the digestive tracts, from mouth to anus. Approximately 1.6 million Americans and 2.2 million Europeans suffer from Crohn’s disease or ulcerative colitis. Most of the patients are suffered in their young adulthood and these incidence rates are constantly rising with significant unmet needs.

Although much improvement has been made in the last 15 years in treating immune-mediated diseases but still much is required to provide safe and effective therapies for those patients who fail to have an effective response to existing treatments. This agreement adds a novel program for potential treatment of Crohn’s Disease and Ulcerative Colitis

Hopefully, MEDI2070 may be an effective treatment for patients with Crohn’s disease.

MedImmune LLC, headquartered in Gaithersburg, Maryland, wholly owned subsidiary of AstraZeneca is a global, innovation-driven biopharmaceutical business that focuses on the discovery, development, and commercialization of small molecule and biologic prescription medicines. MedImmune is the global biologics research and development arm of AstraZeneca, mainly focuses on three core therapeutic areas: Oncology; Respiratory, Inflammation and Autoimmune; and Cardiovascular and Metabolic Disease.

AstraZeneca is a global, science-led biopharmaceutical company, focusing three therapy areas – Respiratory, Cardiovascular & Metabolic Diseases, and Oncology. The Company is also working towards inflammation, infection and neuroscience through numerous collaborations operate in over 100 countries and its innovative medicines are comforting millions of patients worldwide.

Allergan plc, headquartered in Dublin, Ireland, is a specialty pharmaceutical company. The Company is engaged in the development, manufacturing, marketing and distribution of pharmaceutical products, medical aesthetics, biosimilar and over-the-counter (OTC) pharmaceutical products for patients around the world. Allergan provides best in class products for gastroenterology, central nervous system, medical aesthetics, eye care, dermatology, women’s health, urology and anti-infective therapeutic categories.

About the Author: Dr. Komal Tomar, Sr. Licensing Associate at IIPRD and Khurana&Khurana, Advocates and IP Attorneys and can be reached at commercialization@iiprd.com

References:

  • https://www.astrazeneca.com/media-centre/press-releases/2016/MedImmune-completes-out-licensing-agreement-with-Allergan-for-MEDI2070-17112016.html
  • https://www.astrazeneca.com/media-centre/press-releases/2016/medimmune-out-licenses-potential-medicine-for-inflammatory-diseases-to-allergan-03102016.html
  • http://www.allergan.com/news/news/thomson-reuters/allergan-plc-enters-into-licensing-agreement-with

Leave a Reply

Your email address will not be published. Required fields are marked *

10 − 5 =

Archives

  • March 2021
  • February 2021
  • January 2021
  • December 2020
  • November 2020
  • October 2020
  • September 2020
  • August 2020
  • July 2020
  • June 2020
  • May 2020
  • April 2020
  • March 2020
  • February 2020
  • January 2020
  • December 2019
  • November 2019
  • October 2019
  • September 2019
  • August 2019
  • July 2019
  • June 2019
  • May 2019
  • April 2019
  • March 2019
  • February 2019
  • January 2019
  • December 2018
  • November 2018
  • October 2018
  • September 2018
  • August 2018
  • July 2018
  • June 2018
  • May 2018
  • April 2018
  • March 2018
  • February 2018
  • January 2018
  • December 2017
  • November 2017
  • October 2017
  • September 2017
  • August 2017
  • July 2017
  • June 2017
  • May 2017
  • April 2017
  • March 2017
  • February 2017
  • January 2017
  • December 2016
  • November 2016
  • October 2016
  • September 2016
  • August 2016
  • July 2016
  • June 2016
  • May 2016
  • April 2016
  • March 2016
  • February 2016
  • January 2016
  • December 2015
  • November 2015
  • October 2015
  • September 2015
  • August 2015
  • July 2015
  • June 2015
  • May 2015
  • April 2015
  • March 2015
  • February 2015
  • January 2015
  • December 2014
  • November 2014
  • October 2014
  • September 2014
  • August 2014
  • July 2014
  • June 2014
  • May 2014
  • April 2014
  • March 2014
  • February 2014
  • January 2014
  • December 2013
  • November 2013
  • October 2013
  • September 2013
  • August 2013
  • July 2013
  • June 2013
  • May 2013
  • April 2013
  • March 2013
  • February 2013
  • January 2013
  • December 2012
  • November 2012
  • September 2012
  • August 2012
  • July 2012
  • June 2012
  • May 2012
  • April 2012
  • March 2012
  • February 2012
  • January 2012
  • December 2011
  • November 2011
  • October 2011
  • September 2011
  • August 2011
  • July 2011
  • June 2011
  • May 2011
  • April 2011
  • March 2011
  • February 2011
  • January 2011
  • December 2010
  • September 2010
  • July 2010
  • June 2010
  • May 2010
  • April 2010